Table 2 Significant enriched Ingenuity canonical pathways
Rank | Ingenuity canonical pathways | −log(P value) | Ratio | Hyper-genes | Hypo-genes |
|---|---|---|---|---|---|
1 | Dopamine-DARPP32 Feedback in cAMP signaling | 3.98 | 0.07 | CREB5, PPP2R2B, CACNA1A | KCNJ2, NOS1, GRIN2A, GUCY1B3, ADCY2, PRKCH, GNAI3, CACNA1D, PRKCG |
2 | Corticotropin releasing Hormone signaling | 2.74 | 0.07 | CREB5 | JUND, NOS1, GUCY1B3, ADCY2, PRKCH, GNAI3, PRKCG |
3 | nNOS signaling in neurons | 2.61 | 0.11 | CAPN3 | NOS1, GRIN2A, PRKCH, PRKCG |
4 | CDK5 signaling | 2.41 | 0.07 | PPP2R2B, CACNA1A | CDK5R1, NGFR, ITGA2, LAMB1, ADCY2 |
5 | Neuregulin signaling | 2.06 | 0.07 | EGFR, ERBB3 | CDK5R1, ITGA2, PRKCH, PRKCG |
6 | PCP pathway | 2.06 | 0.08 | JUND, FZD10, RSPO3, WNT7B, WNT9B | |
7 | Maturity onset diabetes of young (MODY) signaling | 2.03 | 0.14 | CACNA1A | GAPDH, CACNA1D |
8 | Regulation of eIF4 and p70S6K signaling | 2.02 | 0.05 | PPP2R2B, FAU | RPS16, RPS13, RPS10, ITGA2, IRS1, RPS19 |
9 | mTOR signaling | 1.85 | 0.05 | PPP2R2B, FAU | RPS16, RPS13, RPS10, IRS1, PRKCH, RPS19, PRKCG |
10 | Amyotrophic lateral sclerosis signaling | 1.84 | 0.06 | CAPN3, CACNA1A | NOS1, GRIN2A, NEFM, CACNA1D |
11 | NF-κB activation by viruses | 1.8 | 0.07 | ITGAV, CR2, ITGA2, PRKCH, PRKCG | |
12 | Phosphatidylethanolamine biosynthesis III | 1.7 | 1 | PTDSS2 | |
13 | Role of CHK proteins in cell cycle checkpoint control | 1.61 | 0.07 | PPP2R2B, RFC4 | E2F3, CHEK1 |
14 | Synaptic long-term depression | 1.6 | 0.05 | IGF1R, PPP2R2B | NOS1, GUCY1B3, PRKCH, GNAI3, PRKCG |
15 | ErbB signaling | 1.53 | 0.06 | EGFR, ERBB3 | NCK2, PRKCH, PRKCG |
16 | Type II diabetes mellitus signaling | 1.51 | 0.05 | PKM | NGFR, ADIPOR2, IRS1, PRKCH, PRKCG |
17 | G beta gamma signaling | 1.49 | 0.06 | EGFR | ADCY2, PRKCH, GNAI3, PRKCG |
18 | p70S6K signaling | 1.48 | 0.05 | EGFR, PPP2R2B | IRS1, PRKCH, GNAI3, PRKCG |
19 | Role of osteoblasts, osteoclasts, and chondrocytes in rheumatoid arthritis | 1.47 | 0.04 | FZD10, NGFR, SMAD5, WNT7B, ITGA2, IL1RAP, WNT9B, TCF7L2, NFATC1 | |
20 | Molecular mechanisms of cancer | 1.46 | 0.04 | RASGRF1, ITGA2, WNT7B, IRS1, E2F3, GNAI3, FZD10, SMAD5, ADCY2, WNT9B, PRKCH, CHEK1, PRKCG | |
21 | nNOS signaling in skeletal muscle cells | 1.45 | 0.13 | CAPN3 | NOS1 |
22 | Factors promoting cardiogenesis in vertebrates | 1.42 | 0.05 | FZD10, SMAD5, PRKCH, TCF7L2, PRKCG | |
23 | RAR activation | 1.41 | 0.04 | REL, ERCC2, SMAD5, NR2F1, ADCY2, PRKCH, RARB, PRKCG | |
24 | Choline degradation I | 1.4 | 0.5 | CHDH | |
25 | Sulfate activation for sulfonation | 1.4 | 0.5 | PAPSS2 | |
26 | Mismatch repair in eukaryotes | 1.4 | 0.13 | RFC4 | MLH1 |
27 | Glioma signaling | 1.37 | 0.05 | IGF1R, EGFR | PRKCH, E2F3, PRKCG |
28 | Netrin signaling | 1.36 | 0.08 | UNC5C, NCK2, NFATC1 | |
29 | Cellular effects of sildenafil (Viagra) | 1.33 | 0.05 | CACNG6, CACNA1A | KCNN1, GUCY1B3, ADCY2, CACNA1D |
30 | GNRH signaling | 1.33 | 0.05 | EGFR, CREB5 | ADCY2, PRKCH, GNAI3, PRKCG |
31 | Protein kinase A signaling | 1.31 | 0.03 | HIST1H1A, CREB5 | PTPN9, TIMM50, NFATC1, GNAI3, AKAP12, NGFR, PTP4A1, ADCY2, PRKCH, TCF7L2, PRKCG |
32 | Ovarian cancer signaling | 1.31 | 0.05 | EGFR | FZD10, WNT7B, MLH1, WNT9B, TCF7L2 |
33 | Colorectal cancer metastasis signaling | 1.3 | 0.04 | EGFR | ADRBK1, APPL1, FZD10, WNT7B, MLH1, ADCY2, WNT9B, TCF7L2 |
34 | Agrin interactions at neuromuscular junction | 1.3 | 0.06 | EGFR, ERBB3 | ITGA2, LAMB1 |
35 | Growth hormone signaling | 1.3 | 0.06 | IGF1R | IRS1, PRKCH, PRKCG |